THIS PAGE BLANK (USPTO)

PCT

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 39/42, C07K 15/00, 15/28	**A1**	(11) International Publication Number: **WO 94/19017**
		(43) International Publication Date: 1 September 1994 (01.09.94)

(21) International Application Number: PCT/US94/01920

(22) International Filing Date: 24 February 1994 (24.02.94)

(30) Priority Data:
08/021,879   24 February 1993 (24.02.93)   US

(71) Applicant: PROGENICS PHARMACEUTICALS, INC. [US/US]; Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(72) Inventors: ALLAWAY, Graham, P.; 1778 Horton Avenue, Mohegan Lake, NY 10547 (US). MADDON, Paul, J.; Apartment 25C, 60 Haven Avenue, New York, NY 10032 (US).

(74) Agent: WHITE, John. P.; Cooper & Dunham, 30 Rockefeller Plaza, New York, NY 10112 (US).

(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.

(54) Title: SYNERGISTIC COMPOSITION OF CD4-BASED PROTEIN AND ANTI-HIV-1 ANTIBODY, AND METHODS OF USING SAME

(57) Abstract

The invention provides compositions having a carrier, a CD4-based protein and an antibody which specifically binds an epitope on an HIV-1 envelope glycoprotein required for fusion of a CD4-containing membrane with a membrane containing the HIV-1 envelope glycoprotein. The invention also provides methods of using the compositions for treating and/or preventing HIV-1 infection and for decontaminating fluids containing HIV-1.

SYNERGISTIC COMPOSITION OF CD4-BASED PROTEIN AND ANTI-HIV-1 ANTIBODY, AND METHODS OF USING SAME

5

Background of the Invention

Throughout this application, various publications are referenced by Arabic numerals. Full citations for these

10 publications may be found at the end of the specification immediately preceding the claims. The disclosure of these publications is hereby incorporated by reference into this application to describe more fully the art to which this invention pertains.

15

i) Early events in HIV infection

HIV-1 is the primary causal agent of Acquired Immunodeficiency Syndrome (AIDS). In infected people, HIV-1

20 infects primarily helper T lymphocytes, monocytes/macrophages and dendritic cells--cells that express surface CD4. HIV-1-infected helper T lymphocytes die, and the loss of these CD4+ T lymphocytes is one marker of the progress of HIV-1 infection. The depletion of these cells is probably

25 an important cause of the loss of immune function, resulting in the development of the opportunistic infections and malignancies which typify AIDS. Unlike helper T lymphocytes, other CD4+ cells such as dendritic cells and monocyte/macrophages may become chronically infected by HIV-

30 1. These cells produce virus over a long period of time and appear to be major reservoirs of virus in vivo (1, 2).

The initial phase of the HIV-1 replicative cycle involves the high affinity interaction between the HIV-1 exterior envelope glycoprotein gp120 and the HIV-1 receptor CD4 (Kd approximately 4×10^{-9} M) (3). Following the attachment of

5   HIV-1 to cell surface CD4, viral and target cell membranes fuse, resulting in the introduction of the viral capsid into the target cell cytoplasm. The process of fusion has not been fully elucidated. There is evidence that when CD4 binds to gp120, a conformational change occurs in gp120 (4).

10   It is probable, by analogy with other enveloped viruses, that this conformational change results in the exposure of the hydrophobic domain of gp41, which then penetrates the target cell membrane. HIV-1 fusion appears to occur at the cell surface in a pH-independent manner, similar to the

15   fusion of well studied viruses such as Semliki Forest Virus, but unlike the fusion of viruses such as Influenza which are endocytosed and require acidic conditions to trigger fusion (5).

20   ii)   <u>CD4-based therapeutics</u>

A number of therapeutic strategies have been proposed using CD4-based molecules to target HIV-1 or HIV-1-infected cells which express gp120. These strategies are advantageous in

25   that they depend on the interaction between CD4 and gp120. This interaction is essential for virus infection, so CD4-based strategies should be effective against most, if not all, strains of HIV-1. Moreover, it is highly unlikely that escape mutants would develop with mutations in gp120

30   which eliminate CD4 binding.

In one example of CD4-containing therapies, a soluble version of the entire extracellular segment of CD4 (V1-V4), termed sCD4, has been developed (6). <u>In vitro</u> experiments

35   demonstrate that: 1) sCD4 acts as a "molecular decoy" by binding to HIV-1 gp120 and inhibiting viral attachment to,

and subsequent infection of, human cells; 2) sCD4 "strips" the viral envelope glycoprotein gp120 from the viral surface; and 3) sCD4 blocks the intercellular spread of virus from HIV-1-infected cells to uninfected cells by
5 inhibiting virus-mediated cell fusion (7).

In addition to in vitro results, experiments with sCD4 in simian immunodeficiency virus (SIV)-infected rhesus monkeys have been described.   These studies demonstrate that
10 administration of sCD4 to SIV-infected rhesus monkeys leads to a diminution of the viral reservoir.

Phase I human clinical trials with sCD4 demonstrate that there is no significant toxicity or immunogenicity
15 associated with the administration of sCD4 at doses as high as 30 mg/day.   Preliminary antiviral studies were inconclusive with respect to CD4 cell count and levels of HIV-1 antigen (8, 9).

20 These in vitro animal and human studies with sCD4 defined some limitations. Specifically, the measured serum half-life of sCD4 is very short (45 minutes in humans following intravenous administration) (8, 9). It is hard to imagine that sCD4 administration alone could eliminate HIV-1 from
25 the body.   Rather, sCD4 would be used to delay or prevent the spread of infection and the development of disease. Therefore a therapeutic regimen would involve regular treatment with sCD4. However, the short half-life of sCD4 would make it difficult to maintain sufficient levels in the
30 plasma to give a therapeutic effect.   This problem is compounded by the fact that higher levels of sCD4 are required to neutralize clinical isolates of HIV-1 as compared to laboratory isolates, although all clinical isolates can be neutralized at some concentration (10). To
35 make a CD4-based molecule with a longer half-life, chimeric CD4-based molecules were made which comprise the gp120-

4

binding region of CD4 and a portion of another protein such as an immunoglobulin molecule. Such molecules also have the advantage of greater avidity for HIV-1 based on the multiple gp120-binding domains which they present, compared to sCD4
5 having only one gp120-binding domain.

For example, dimeric CD4-human IgG1 heavy chain fusion proteins have been described (11, 12). These molecules include a molecule containing the V1V2 domains of CD4 fused
10 to the hinge, CH2 and CH3 domains of a gamma1 heavy chain (12). These fusion proteins have been used successfully to block HIV-1 infection *in vitro*, and in one case to block the infection of Chimpanzees by a laboratory strain of HIV-1 (13). The CD4-immunoglobulin chimeras have a significantly
15 longer half-life *in vivo* than does sCD4 (11). These fusion proteins retain various effector functions of immunoglobulin molecules, such as Fc receptor binding, cell-mediated transfer via an Fc receptor-dependent mechanism, and complement activation (12). Many of the functions of
20 antibodies are mediated through their interaction with Fc receptors. These receptors are found on a variety of cells including macrophages, other leukocytes, platelets and placental trophoblasts (14). The Fc receptor binds to the Fc portion of immunoglobulins and the complex can trigger a
25 variety of responses depending on cell type. In the case of macrophages, the response can include phagocytosis and antibody-dependant cellular cytotoxicity (ADCC). With placental trophoblasts, IgG1 binding leads to transfer of the antibody to the fetus.
30
The binding of CD4-IgG1 chimeras to Fc receptors has potential drawbacks. In particular, this binding could concentrate virus on Fc receptor-bearing cells such as macrophages, and placental trophoblasts enhance the HIV-1
35 infection of these cells. In pregnant women, placental transfer of CD4-IgG1 chimeras, when bound to HIV-1, might

lead to increased HIV-1 infection of the fetus.

Therefore, CD4-based proteins with little or no effector functions were developed, based on human IgG2 which exhibits little or no Fc receptor binding. These molecules also have an advantage over IgG1-based molecules, in that human IgG2 antibodies exhibit minimal allotypic variation while human IgG1 antibodies have considerable variation. IgG2-based chimeras might be less immunogenic than IgG1 chimeras.

Specifically, a CD4-gamma2 chimeric heavy chain homodimer which contains the V1V2 domains of CD4 linked to the hinge, CH2, and CH3 domains from a human gamma2 heavy chain was produced. A CD4-IgG2 chimeric heterotetramer was also produced. This heterotetramer is composed of chimeric light and heavy chains which are assembled into a tetramer. The heavy chains consist of a segment containing the V1 and V2 domains of CD4 which is fused to a segment containing the CH1, hinge, CH2 and CH3 domains of a human gamma2 heavy chain. The light chains contain the V1 and V2 domains of CD4 fused to the entire constant domain of human kappa light chains.

These CD4-gamma2 chimeric heavy chain homodimers and CD4-IgG2 chimeric heterotetramers block HIV-1 infection and syncytium formation. They have terminal half-lives of 1 or more days in rabbits and do not interact with high affinity Fc receptors on the human monocyte cell line U937. The CD4-IgG2 chimeric heterotetramers may possess increased serum half-lives in humans and increased avidity for HIV-1 as compared with the heavy chain homodimers.

iii)   <u>Neutralizing antibodies to HIV-1</u>

During the course of HIV-1 infection in humans, a humoral immune response develops which includes the presence of

antibodies which can neutralize HIV-1 infection (15). Early
in infection, antibodies to the third variable loop (V3
loop) of gp120 are often detected. Anti-V3 loop antibodies
are usually type-specific and neutralize the initial HIV-1
5 immunogen strain as well as closely related strains (15).
In vivo, it appears that escape mutants with modified V3
loops are constantly being selected which are resistant to
anti-V3 loop antibodies directed against previous strains.
This may be one reason why the immune response to HIV-1 does
10 not succeed in controlling HIV-1 infections.

Neutralizing antibodies to the V3 loop do not block
attachment, but appear to act at the fusion step of viral
entry (16). This and other data indicate that the V3 loop
15 may have a direct role in fusion, perhaps by interacting
with a cellular molecule other than CD4. Mutations in the
V3 loop can block fusion. Some reports have suggested that
the V3 loop must be cleaved by a cell surface protease prior
to fusion, but this hypothesis remains to be proven.
20

Later in HIV-1 infection, neutralizing antibodies are often
detected which target the CD4-binding domain of gp120 and
block attachment. These antibodies can neutralize a range
of viral strains, probably because the CD4-binding domain of
25 gp120 is highly conserved (15). However, it is clear that
these antibodies do not bind to precisely the same site as
does CD4 (17), perhaps because CD4 binds to a narrow canyon
in gp120 which is too small for penetration by antibodies.
Instead, these antibodies may bind to the lip of the canyon
30 where some variability can be tolerated without preventing
CD4 binding (17). Therefore, while these antibodies can
neutralize a wider variety of HIV-1 strains than antibodies
to the V3 loop, they are not as broadly neutralizing as CD4-
based molecules. It is unlikely that HIV-1 mutants could
35 develop which are completely resistant to CD4-based
molecules yet remain infectious.

7

Neutralizing antibodies are also found which are directed to
other domains of HIV-1 envelope glycoproteins during the
course of HIV-1 infection. Of these, antibodies to gp41 are
particularly important. These neutralizing antibodies act
5   at the fusion step rather than at the attachment step, and
presumably prevent insertion of the fusogenic domain of gp41
into the target membrane. Moreover, unlike anti-V3 loop
antibodies, anti-gp41 antibodies can often neutralize a wide
range of viral strains (18). This broad neutralization
10   probably results from the more conservative nature of the
fusogenic domain of gp41, similar to the CD4-binding domain
of gp120 discussed above.

iv)   **Synergistic compositions of CD4-based proteins and**
15   **antibodies to gp120 and gp41 for prevention and**
         treatment of HIV-1 infections

Recent   studies   have   demonstrated   that   neutralizing
antibodies   to   the   CD4-binding   domain   of   gp120,   in
20   combination   with   anti-V3   loop   antibodies,   can   act
synergistically in blocking HIV-1 infection (19-21). As
potential   therapeutics,   these   antibodies   have   some
drawbacks. As discussed above, antibodies to the V3 loop
neutralize a limited number of HIV-1 strains. The high
25   variability of the V3 loop means that therapeutic use of
antibodies to this loop will lead to the selection of
resistant HIV-1 strains with different V3 loop sequences.
To a lesser extent, this is also true with antibodies to the
CD4-binding domain of gp120. As discussed above, antibodies
30   to   the   CD4-binding   domain   of   gp120   act   by   blocking
attachment. Antibodies to the V3 loop neutralize infection
by blocking fusion.

The subject invention provides a composition comprising (a)
35   a CD4-based protein, and (b) an antibody capable of forming
a complex with an epitope present on an HIV-1 envelope

8

glycoprotein and of specifically inhibiting HIV-1-envelope glycoprotein-mediated membrane fusion. The composition of the subject invention is a synergistic composition of a molecule which blocks attachment (CD4-based protein) and a

5 molecule which blocks fusion (antibody capable of forming a complex with an epitope present on an HIV-1 envelope glycoprotein). The composition of the subject invention has numerous clinical uses, as described infra.

10

9

Summary of the Invention

The subject invention provides a composition comprising (a)
5 a carrier, (b) a CD4-based protein, and (c) an antibody
which specifically binds to an epitope present on an HIV-1
envelope glycoprotein and required for the fusion of a CD4-
containing membrane with a membrane containing the HIV-1
envelope glycoprotein, the ratio of CD4-based proteins to
10 antibodies in the composition being such that the ratio of
gp120-binding sites on the CD4-based proteins to epitope-
binding sites on the antibodies is between about 0.01 and
about 100.

15 Desirably, the ratio of gp120-binding sites to epitope-
binding sites is between about 0.1 and about 10. Thus, the
ratio of gp120-binding sites to epitope-binding sites may be
between about 1 and about 10. For example, the ratio may be
between about 1.5 and about 6.
20

In one embodiment, the carrier is a pharmaceutically
acceptable carrier. For example, the composition may be a
liquid and the pharmaceutically acceptable carrier may be an
aqueous buffer. Alternatively, the composition may be a
25 solid and the pharmaceutically acceptable carrier may be an
excipient.

In one embodiment, the CD4-based protein is sCD4. In
another embodiment, the CD4-based protein is a CD4-
30 immunoconjugate.

For example, the CD4-immunoconjugate may be a CD4-gamma1
chimeric heavy chain homodimer. The CD4-immunoconjugate may
also be a heterotetramer comprising two heavy chains and two
35 light chains, both heavy chains being either a) IgG1 heavy
chains or b) chimeric CD4-IgG1 heavy chains, and both light

chains being a) kappa light chains, b) lambda light chains
c) chimeric CD4-kappa light chains, or d) chimeric CD4-
lambda light chains, with the proviso that either both heavy
chains or both light chains or all four chains are CD4

5   chimeras.   The heterotetramer may be a heterotetramer
wherein the chimeric CD4-IgG1 heavy chains are encoded by
the expression vector designated CD4-IgG1HC-pRcCMV (ATCC No.
75192), and the chimeric CD4-kappa light chains are encoded
by the expression vector designated CD4-kLC-pRcCMV (ATCC No.

10 75194).

The CD4-immunoconjugate may be a CD4-gamma2 chimeric heavy
chain homodimer.   The CD4-gamma2 chimeric heavy chain
homodimer may be the CD4-gamma2 chimeric heavy chain

15 homodimer whose chains are encoded by the expression vector
designated CD4IgG$_2$-pcDNA1 (ATCC No. 40952).

The CD4-immunoconjugate may also be a heterotetramer
comprising two heavy chains and two light chains, both heavy

20 chains being either a) IgG2 heavy chains or b) chimeric CD4-
IgG2 heavy chains, and both light chains being a) kappa
light chains, b) lambda light chains c) chimeric CD4-kappa
light chains, or d) chimeric CD4-lambda light chains, with
the proviso that either both heavy chains or both light

25 chains or all four chains are CD4 chimeras.   The
heterotetramer may be a heterotetramer wherein the chimeric
CD4-IgG2 heavy chains are encoded by the expression vector
designated CD4-IgG2HC-pRcCMV (ATCC No. 75193), and the
chimeric CD4-kappa light chains are encoded by the

30 expression vector designated CD4-kLC-pRcCMV (ATCC No.
75194).

In one embodiment, the antibody is capable of forming a
complex with an epitope present on HIV-1 gp120 envelope

35 glycoprotein.   For example, the antibody may be capable of
forming a complex with an epitope present on the V3 loop of

11

HIV-1 gp120 envelope glycoprotein.

In the preferred embodiment, the antibody is capable of forming a complex with an epitope present on HIV-1 gp41
5   envelope glycoprotein. For example, the antibody may be capable of forming a complex with an epitope present on HIV-1 gp41 envelope glycoprotein, said epitope comprising the amino acid sequence ELDKWA. The antibody may be the monoclonal antibody designated 2F5.
10

The subject invention also provides a method of treating a subject which comprises administering to the subject an amount of the composition of the subject invention effective to reduce the likelihood of the subject's becoming infected
15   with HIV-1.

The subject may be a newborn infant. The subject may also be a medical practitioner.

20   The subject invention further provides a pharmaceutical composition comprising an amount of the composition of the subject invention effective to reduce the likelihood of a subject's becoming infected with HIV-1.

25   The subject invention further provides a method of treating an HIV-infected subject, which comprises administering to the subject an amount of the composition of the subject invention effective to reduce the rate of spread of HIV-1 infection in the subject.
30

The subject invention further provides a pharmaceutical composition comprising an amount of the composition of the subject invention effective to reduce the rate of spread of HIV-1 infection in an HIV-1-infected subject.
35

The subject invention further provides a method of

12

decontaminating a fluid containing HIV-1, which comprises contacting the fluid with the composition of the subject invention, under conditions such that the composition of the subject invention forms a complex with the HIV-1 therein,

5 thereby decontaminating the fluid.

Finally, the subject invention provides a method of decontaminating a fluid containing HIV-1, which further comprises contacting the fluid with the composition of the

10 subject invention, under conditions such that the composition of the subject invention forms a complex with the HIV-1 therein, and removing the complex so formed from the fluid, thereby decontaminating the fluid.

Brief Description of th Figures:

Figure 1: Inhibition of HIV-1-envelope induced cell fusion by sCD4 (▲-▲), an antibody to the V3 loop of HIV-1 gp120
5 (designated 9205) (●-●) and a 1:1 composition (on a mass basis) of the two (◆-◆).

Figure 2: Median effect plot of data in Figure 1. The Log (fraction inhibited/fraction uninhibited) is plotted against
10 Log dose for sCD4 alone (▲-▲), the anti-V3 loop antibody 9205 (●-●) and a 1:1 composition (on a mass basis) of the two (◆-◆).

Figure 3: Combination index plotted against fractional
15 inhibition for the sCD4/9205 synergy analysis. The method of Chou and Talalay (23) was used for the calculations, where a CI of 1 indicates additivity, <1 indicates synergy and >1 indicates antagonism. The more conservative mutually non-exclusive calculation method was used.

20

Detailed Descripti n of the Invention

The plasmids $CD4-IgG_1HC-pRcCMV$, $CD4-kLC-pRcCMV$, $CD4IgG_2-$
5   pcDNA1 and $CD4-IgG_2HC-pRcCMV$ were deposited pursuant to, and
in satisfaction of, the requirements of the Budapest Treaty
on the International Recognition of the Deposit of
Microorganisms for the Purposes of Patent Procedure with the
American Type Culture Collection (ATCC), 12301 Parklawn
10 Drive, Rockville, Maryland 20852 under ATCC Accession Nos.
75192, 75194, 40952, and 75193, respectively. The plasmids
$CD4-IgG_1HC-pRcCMV$, $CD4-kLC-pRcCMV$, and $CD4-IgG_2HC-pRcCMV$
were deposited with the ATCC on January 30, 1992. The
plasmid $CD4IgG_2-pcDNA1$ was deposited with the ATCC on
15 January 31, 1991.

Specifically, the subject invention provides a composition
comprising (a) a carrier, (b) a CD4-based protein, and (c)
an antibody which specifically binds to an epitope present
20 on an HIV-1 envelope glycoprotein and required for the
fusion of a CD4-containing membrane with a membrane
containing the HIV-1 envelope glycoprotein, the ratio of
CD4-based proteins to antibodies in the composition being
such that the ratio of gp120-binding sites on the CD4-based
25 proteins to epitope-binding sites on the antibodies is
between about 0.01 and about 100.

As used herein, CD4 means the mature, native, membrane-bound
CD4 protein comprising a cytoplasmic domain, a hydrophobic
30 transmembrane domain, and an extracellular domain which
binds to HIV-1 gp120 envelope glycoprotein.

As used herein, a CD4-based protein is any protein
comprising at least one sequence of amino acid residues
35 corresponding to that portion of CD4 which is required for
CD4 to form a complex with the HIV-1 gp120 envelope

15

glycoprotein. If the CD4-based protein is sCD4, then the sequence of amino acid residues corresponding to that portion of CD4 which is required for CD4 to form a complex with the HIV-1 gp120 envelope glycoprotein is the amino acid
5   sequence from +1 to about +106. As used herein, sCD4 means a water soluble, extracellular fragment of human CD4. If the CD4-based protein comprises a portion of a non-CD4 protein, then the sequence of amino acid residues corresponding to that portion of CD4 which is required for
10 CD4 to form a complex with the HIV-1 gp120 envelope glycoprotein is the amino acid sequence from +1 to about +17⌐ Thus, a CD4-based protein is a protein which includes one or more gp120-binding sites.

15 Examples of CD4-based proteins include, but are in no way limited to, the CD4-based proteins discussed _infra_.

As used herein, "fusion of a CD4-containing membrane with a membrane containing the HIV-1 envelope glycoprotein" means
20 the hydrophobic joining and integration of the CD4-containing membrane with the membrane containing the HIV-1 envelope glycoprotein, and not the CD4-HIV-1 envelope glycoprotein-mediated binding of the CD4-containing membrane to the membrane containing the HIV-1 envelope glycoprotein,
25 which binding is a prerequisite for the fusion. The membrane containing the HIV-1 envelope glycoprotein may be an HIV-1 viral membrane. The membrane containing the HIV-1 envelope glycoprotein may also be a cellular membrane containing the HIV-1 envelope glycoprotein.
30
As used herein, the ratio of gp120-binding sites on the CD4-based protein to HIV-1 envelope glycoprotein epitope-binding sites on the antibody means the ratio of the number of moles of gp120-binding sites on the CD4-based protein in the
35 composition to the number of moles of HIV-1 envelope glycoprotein-binding sites on the antibody in the

composition. For example, if a composition comprises x moles of a CD4-based protein having one gp120-binding site per molecule, and y moles of an antibody having two HIV-1 envelope glycoprotein epitope-binding sites per antibody,

5 then the ratio of gp120-binding sites on the CD4-based protein to HIV-1 envelope glycoprotein epitope-binding sites on the antibody would be x:2y.

Desirably, the ratio of gp120-binding sites to epitope-

10 binding sites is between about 0.1 and about 10. Thus, the ratio of gp120-binding sites to epitope-binding sites may be between about 1 and about 10. For example, the ratio may be between about 1.5 and about 6.

15 In one embodiment, the carrier is a pharmaceutically acceptable carrier. For example, the composition may be a liquid and the pharmaceutically acceptable carrier may be an aqueous buffer. Alternatively, the composition may be a solid and the pharmaceutically acceptable carrier may be an

20 excipient.

Pharmaceutically acceptable carriers are well known to those skilled in the art and include, but are not limited to. 0.01-0.1M and preferably 0.05M phosphate buffer or 0.8%

25 saline. Additionally, such pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic

30 esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated

35 Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as

17

those bas d on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, chelating agents, inert gases and the like.

5

In one embodiment, the CD4-based protein is sCD4. In another embodiment, the CD4-based protein is a gp120-binding fragment of sCD4.

10   In another embodiment, the CD4-based protein is a CD4-immunoconjugate. As used herein, a CD4-immunoconjugate is a molecule which comprises the gp120-binding portion of CD4 and an Fc immunoglobulin domain, or biologically active portion thereof.

15

The CD4-immunoconjugate may be a CD4-gamma1 chimeric heavy chain homodimer. The CD4-immunoconjugate may also be a heterotetramer comprising two heavy chains and two light chains, both heavy chains being either a) IgG1 heavy chains
20   or b) chimeric CD4-IgG1 heavy chains, and both light chains being a) kappa light chains, b) lambda light chains c) chimeric CD4-kappa light chains, or d) chimeric CD4-lambda light chains, with the proviso that either both heavy chains or both light chains or all four chains are CD4 chimeras.
25   The heterotetramer may be a heterotetramer wherein the chimeric CD4-IgG1 heavy chains are encoded by the expression vector designated CD4-IgG1HC-pRcCMV (ATCC No. 75192), and the chimeric CD4-kappa light chains are encoded by the expression vector designated CD4-kLC-pRcCMV (ATCC No.
30   75194).

The CD4-immunoconjugate may be a CD4-gamma2 chimeric heavy chain homodimer. The CD4-gamma2 chimeric heavy chain homodimer may be the CD4-gamma2 chimeric heavy chain
35   homodimer whose chains are encoded by the expression v ctor designated CD4IgG$_2$-pcDNA1 (ATCC No. 40952).

18

The CD4-immunoconjugate may also be a heterotetramer comprising two heavy chains and two light chains, both heavy chains being either a) IgG2 heavy chains or b) chimeric CD4-IgG2 heavy chains, and both light chains being a) kappa

5   light chains, b) lambda light chains c) chimeric CD4-kappa light chains, or d) chimeric CD4-lambda light chains, with the proviso that either both heavy chains or both light chains or all four chains are CD4 chimeras.   The heterotetramer may be a heterotetramer wherein the chimeric

10   CD4-IgG2 heavy chains are encoded by the expression vector designated CD4-IgG2HC-pRcCMV (ATCC No. 75193), and the chimeric CD4-kappa light chains are encoded by the expression vector designated CD4-kLC-pRcCMV (ATCC No. 75194).

15

In the preferred embodiment, the CD4-immunoconjugate is either a CD4-gamma2 chimeric heavy chain homodimer or a CD4-IgG2 chimeric heterotetramer.

20   In one embodiment, the antibody is capable of forming a complex with an epitope present on HIV-1 gp120 envelope glycoprotein.   The antibody may be capable of forming a complex with an epitope present on the V3 loop of HIV-1 gp120 envelope glycoprotein.

25

In the preferred embodiment, the antibody is capable of forming a complex with an epitope present on HIV-1 gp41 envelope glycoprotein.   The antibody may be capable of forming a complex with an epitope present on HIV-1 gp41

30   envelope glycoprotein, said epitope comprising the amino acid sequence ELDKWA.   The antibody may be the monoclonal antibody designated 2F5.

The subject invention also provides a method of treating a

35   subject which comprises administering to the subject an amount of the composition of the subject invention effective

to reduce the likelihood of the subject's becoming infected
with HIV-1.

As used herein, reducing the likelihood of the subject's
5 becoming infected with HIV-1 means reducing the likelihood
of the subject's becoming infected with HIV-1 by at least
two-fold. For example, if a subject has a 1% chance of
becoming infected with HIV-1, a two-fold reduction in the
likelihood of the subject's becoming infected with HIV-1
10 would result in the subject's having a 0.5% chance of
becoming infected with HIV-1. In a preferred embodiment of
this invention, reducing the likelihood of the subject's
becoming infected with HIV-1 means reducing the likelihood
of the subject's becoming infected with HIV-1 by at least
15 ten-fold.

The subject may be a human. The subject may also be an
individual recently exposed to HIV-1.

20 In one embodiment, the subject is a newborn infant. The
newborn infant may be a newborn infant born to an HIV-1-
infected mother.

In another embodiment, the subject is a medical
25 practitioner. The medical practitioner may be a medical
practitioner exposed to an HIV-1-containing bodily fluid. As
used herein, the term "medical practitioner" includes, but
is in no way limited to, doctors, dentists, surgeons,
nurses, medical laboratory assistants, and students in
30 health care programs.

As used herein, "the subject's becoming infected with HIV-1"
means the invasion of the subject's own cells by HIV-1.

35 As used herein, administering may be effected or performed
using any of the various methods known to those skilled in

the art. The administering may comprise administering intravenously. The administering may also comprise administering intramuscularly. The administering may further comprise administering subcutaneously.

5

The amount of the composition of the subject invention effective to reduce the likelihood of the subject's becoming infected with HIV-1 may be readily determined using methods well known to those skilled in the art. In the preferred

10 embodiment, the amount is between about 0.1 mg/kg and 10mg/kg of body weight.

The subject invention further provides a pharmaceutical composition comprising an amount of the composition of the

15 subject invention effective to reduce the likelihood of th subject's becoming infected with HIV-1.

The subject invention further provides a method of treating an HIV-infected subject, which comprises administering to

20 the subject an amount of the composition of the subject invention effective to reduce the rate of spread of HIV-1 infection in the subject.

The subject may be a human. As used herein, an "HIV-

25 infected subject" means an individual having at least one of his own cells invaded by HIV-1.

As used herein, reducing the rate of spread of HIV-1 infection in the subject means reducing the rate of spread

30 by at least two-fold. For example, if the rate of spread of HIV-1 infection were x cells invaded by HIV-1 per given unit of time, a two-fold reduction in the rate of spread of HIV-1 infection would result in 1/2x cells invaded by HIV-1 per given unit of time. In a preferred embodiment of this

35 invention, reducing the rate of spread of HIV-1 infection in the subject means reducing the rate of spread by at least

ten-fold.

The amount of the composition of the subject invention
effective to reduce the rate of spread of HIV-1 infection in
5 the subject may be readily determined using methods well
known to those skilled in the art.   In the preferred
embodiment, the amount is between about 0.1 mg/kg and
10mg/kg of body weight.

10 The subject invention further provides a pharmaceutical
composition comprising an amount of the composition of the
subject invention effective to reduce the rate of spread of
HIV-1 infection in an HIV-1-infected subject.

15 The subject invention further provides a method of
decontaminating a fluid containing HIV-1, which comprises
contacting the fluid with the composition of the subject
invention, under conditions such that the composition of the
subject invention forms a complex with the HIV-1 therein,
20 thereby decontaminating the fluid.

As used herein, "decontaminating a fluid containing HIV-1"
means either (a) rendering the HIV-1 in the fluid unable to
invade cells, (b) removing the HIV-1 from the fluid, or (c)
25 a combination of (a) and (b).

As used herein, the term "fluid" includes, but is not
limited to, a bodily fluid. A bodily fluid is any fluid
which is present in the human body and is capable of
30 containing infectious HIV in an HIV-infected patient. Bodily
fluids include, but are not limited to, blood or derivatives
thereof, saliva, cerebrospinal fluid, tears, vaginal
secretions, urine, alveolar fluid, synovial fluid, pleural
fluid and bone marrow. The fluid may be a fluid which is to
35 be administered to a subject.

Conditions under which the composition of the subject invention would form a complex with HIV-1 are well known to those skilled in the art.

5   Finally, the subject invention provides a method of decontaminating a fluid containing HIV-1, which further comprises contacting the fluid with the composition of the subject invention, under conditions such that the composition of the subject invention forms a complex with
10   the HIV-1 therein, and removing the complex so formed from the fluid, thereby decontaminating the fluid.

Removing the complex formed between the composition of the subject invention and the HIV-1 from the fluid may be
15   accomplished according to methods well known to those skilled in the art. By way of example, the complex may be removed by contacting the fluid containing the complex with an immobilized antibody specific for the complex, thereby removing the complex from the fluid. An antibody specific
20   for the complex may be obtained according to methods well known to those skilled in the art. Furthermore, methods of immobilizing antibodies are well known to those skilled in the art.

25   This invention will be better understood by reference to the Experimental Details which follow, but those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the invention as described more fully in the claims which follow thereafter.
30

23

Experimental Details

A. Materials and Methods

5

i) Reagents

a) General

10 sCD4, CD4-gamma1 chimeric heavy chain homodimers, CD4-gamma2
chimeric heavy chain homodimers and CD4-IgG2 chimeric
heterotetramers were obtained from Progenics
Pharmaceuticals, Inc. (Tarrytown, New York). Mouse antibody
[9205] to the V3 loop of gp120, derived from the HIV-
15 1$_{HTLVIIIB}$ isolate (24), was obtained from DuPont NEN Research
Products (Wilmington, Delaware). Human antibody 2F5 to a
conserved epitope of HIV-1 gp41 (18) was obtained from Viral
Testing Systems Corporation (Houston, Texas) and from
Waldheim Pharmazeutika (Vienna, Austria).

20

b) sCD4

Soluble CD4 (a genetically-engineered, water-soluble
extracellular fragment of human CD4) is disclosed, for
25 example, in Patent Cooperation Treaty International
Publication No. WO 88/01304. Soluble CD4 is also
commercially available.

Soluble CD4, also designated sCD4, may be produced by
30 truncating pT4B (ATCC No. 68389) after the V4J4 domain.
Such DNA fragments terminate before the transmembrane
segment, which begins at approximately nucleotide position
1264.

35 Purification and characterization of soluble CD4 fragments
is greatly enhanced by constructing a cell line (preferably

24

mammalian) which overexpresses the secreted protein
fragment. Strategies which allow the overexpression of
proteins may be employed in bacteria, yeast, insect and
mammalian systems. Inducible expression systems may also be
5   employed in bacteria and yeast to overproduce proteins which
may be toxic if constitutively expressed. Overexpression of
soluble CD4 fragments may be accomplished by amplifying a
soluble CD4 expression vector, resulting in constitutive
overexpression. The amplification of dihydrofolate
10   reductase (dhfr) genes by growth in progressively increased
concentrations of the drug methotrexate, an antagonist of
dhfr, is widely employed. Since the amplified unit is not
limited to dhfr coding sequences, this approach results in
the coamplification of sequences adjacent to them.
15   Therefore, dhfr may be used as a selectable marker and as a
means of coamplifying newly introduced sequences. This
strategy may be successfully employed to increase the
expression of several different genes cotransformed with
dhfr plasmids.
20

Using recombinant DNA technology, a vector expressing a
secreted, soluble, extracellular fragment of CD4 encoded by
the human cDNA clone pT4B may be generated. Base pairs 1-
1252 of pT4B encode the leader peptide of CD4 needed for the
25   synthesis of secreted protein, as well as the extracellular
portion of CD4 encompassing the four VJ-like domains (V1J1-
V4J4), but not the transmembrane and cytoplasmic regions
which anchor the protein in the membrane. This vector
contains sequences encoding the extracellular portion of the
30   CD4 protein which contains the HIV binding domain. These
sequences are placed downstream from the SV40 early region
promoter. In addition, a TAA termination codon followed by
the polyadenylation region of the bovine growth hormone gene
is placed downstream from the truncated CD4 cDNA to provide
35   the signals necessary for the termination of protein
synthesis, transcription termination, and polyadenylation of

the RNA transcript. The resulting soluble CD4 minigene is then ligated to the mouse dihydrofolate reductase (dhfr) gene to generate a plasmid capable of being amplified after introduction into dhfr-deficient (dhfr-) Chinese hamster
5   ovary (CHO) cells.

For example, the 1.8 kb EcoRI-BamHI fragment of pT4B, which contains the entire CD4 coding sequence, is inserted between the StuI and BclI sites of the mammalian expression vector
10   DSP modified to contain the SV-40 early promoter and the bovine growth hormone polyadenylation sequence. Through the use of synthetic linkers, the HaeII (bp 124) - HpaII (bp 1252) fragment of pT4B is inserted between the KpnI and XbaI sites of the plasmid pUC18. A soluble CD4 expression vector
15   is created by ligating:

1.   a 0.95 kb BglII - SacI fragment of modified DSP which contains the 1.8 kb EcoRI-BamHI fragment of pT4B (this segment contains the SV40 early
20   promoter, the CD4 leader sequence, and the amino terminal portion of the extracellular CD4 sequence);

2.   the 0.66 kb SacI - XbaI fragment of the pUC18
25   plasmid containing the HaeII-HpaII fragment of pT4B (this segment contains the carboxy terminal portion of the extracellular CD4 sequence followed by a TAA termination codon inserted after valine 371); and

30   3.   the 2.48 kb BglII - XbaI fragment of modified DSP which contains the bovine growth hormone polyadenylation sequence.

Finally, the 2.2 kb BglII - BamHI fragment from another
35   modified DSP containing a mouse dhfr expression cassette (ß-globin promoter - mouse dhfr coding region - SV40

polyadenylation region) flanked by BglII and BamHI sites, is inserted into the BamHI site of a plasmid to create a soluble CD4 expression plasmid.

5   DXB-11, a clone of Chinese hamster ovary cells deficient in dhfr, is transfected with the soluble CD4 expression plasmid. The DXB-11 transformants are then grown in F12 medium, without hypoxanthine or thymidine, containing 10% dialyzed fetal bovine serum. Clones are selected and
10   subjected to stepwise increasing concentrations of methotrexate (mtx), an antagonist of dhfr, to select for stable transformants which have amplified the newly introduced dhfr gene and adjacent soluble CD4 sequences.

15   Purification of the sCD4 protein was performed using ion exchange chromatography. Ion exchange chromatography is well known to those skilled in the art.

     c)   CD4-IgG1 Chimeras
20

     Co-expression of CD4-IgG1HC-pRcCMV and CD4-kLC-pRcCMV in mammalian cells to produce CD4-IgG1 chimeric heterotetramer

     Stable expression
25   Dhfr- Chinese hamster ovary cells (CHO) are transfected with 20 micrograms of CsCl purified DNA in a ratio of 1000:1000:1 CD4-IgG1HC-pRcCMV:CD4-kLC-pRcCMV:p410 (p410 is an expression plasmid containing the dhfr gene), although other ratios may also be used. At approximately 3-5 days post-transfection,
30   cells are placed in selective medium (nucleoside-free alpha MEM containing 5% dialyzed fetal calf serum). At approximately 10-15 days post-selection, individual cell clones are picked. The clones are then analyzed for stable expression of CD4-IgG1 chimeric heterotetramers by several
35   screening techniques, such as ELISA and precipitation with Protein A-sepharose beads followed by SDS-PAGE under

27

reducing or non-reducing conditions. Clones expressing the highest levels are subjected to successive rounds of amplification of the newly introduced DNA sequences in increasing concentrations of methotrexate. Stable CHO cell
5   lines are thus generated which secrete high levels of CD4-IgG1 chimeric heterotetramer.

Purification of CD4-IgG1 chimeric heterotetramers from CHO conditioned media

10   CD4-IgG1 chimeric heterotetramers are purified using Protein A-Sepharose column chromatography. CHO cells secreting CD4-IgG1 chimeric heterotetramers are grown to high density in roller bottles in medium containing alpha MEM with 5% IgG-free fetal calf serum. Conditioned media is collected,
15   clarified by centrifugation, and diluted 1:1 with PBS either with or without detergent (i.e. Tween) in this and subsequent buffers. The diluted media is then applied to a 5ml column of Protein A-Sepharose fast flow previously equilibrated with PBS, at a flow rate of 60ml/hour. After
20   extensive washing, the bound material is eluted with 100mM glycine/HCl, pH 3.5, directly into an aliquot of 1M Tris.HCl pH 8.0 to immediately neutralize the eluted fractions. Fractions are then analyzed by SDS-PAGE under reducing and non-reducing conditions followed by silver staining and
25   pooled.

The pooled fractions were then applied to a 10 ml column of S-sepharose fast flow previously equilibrated with 50mM BES pH 7.0 at a flow rate of 120ml/hr. After application of the
30   sample, a step elution gradient (consisting of the following 4 steps: 5 column volumes of 50mM BES pH 7.0, 4 column volumes of 50mM BES pH 7.0, 100mM NaCl, 6 column volumes of 50mM BES pH 7.0 225mM NaCl, followed by 8 column volumes of 50mM BES pH 7.0, 500mM NaCl) was employed for specific
35   elution of the CD4-IgG1 chimeric heterotetramer. The CD4-IgG1 chimeric heterotetramer was eluted from the column in

28

50mM BES pH 7.0, 500mM NaCl. The peak fractions were then pooled and concentrated to yield a final protein concentration of at least 1 mg/ml.

5 d) CD4-IgG2 Chimeras

Stable expression

Dhfr- Chinese hamster ovary cells (CHO) were transfected with 20 micrograms of CsCl-purified DNA in a 1000:1 molar
10 ratio of CD4IgG2-pcDNA1:p410 (p410 is an expression plasmid containing the dhfr gene), although other ratios may also be used. Approximately 3-5 days post-transfection, cells were placed in selective medium (nucleoside-free alpha MEM containing 5% dialyzed fetal calf serum). Approximately
15 10-15 days post-selection, individual cell clones were picked and analyzed for stable expression of CD4-gamma2 chimeric heavy chain homodimer by several screening techniques, such as ELISA and precipitation with Protein A-sepharose beads followed by SDS-PAGE under reducing and non-
20 reducing conditions. Clones expressing the highest levels were subjected to successive rounds of amplification of the newly introduced DNA sequences in increasing concentrations of methotrexate. Stable CHO cell lines were thus generated which secrete between 10-100 micrograms/milliliter of CD4-
25 gamma2 chimeric heavy chain homodimer.

Purification of CD4-gamma2 chimeric heavy chain homodimer from CHO conditioned media

CD4-gamma2 chimeric heavy chain homodimer was purified by
30 column chromatography. CHO cells secreting CD4-gamma2 chimeric heavy chain homodimer were grown to high density in roller bottles in medium containing alpha MEM with 5% IgG-free fetal calf serum. Conditioned media was collected, clarified by centrifugation, and diluted 1:1 with PBS either
35 with or without detergent (i.e. Tween) in this and subsequent buffers. The diluted media was then applied to

a 5ml column of Protein A-Sepharose fast flow previously equilibrated with PBS, at a flow rate of 60ml/hour. After extensive washing, the specifically bound material was eluted with 100mM glycine/HCl, pH 3.5, directly into an
5   aliquot of 1M Tris.HCl pH 8.0 to immediately neutralize the eluted fractions. The fractions were then analyzed by SDS-PAGE under reducing and non-reducing conditions followed by silver staining and pooled.

10   The pooled fractions were then applied to a 10 ml column of S-sepharose fast flow previously equilibrated with 50mM BES pH 7.0 at a flow rate of 120ml/hr. After application of the sample, a step elution gradient (consisting of the following 4 steps: 5 column volumes of 50mM BES pH 7.0, 4 column
15   volumes of 50mM BES pH 7.0, 100mM NaCl, 6 column volumes of 50mM BES pH 7.0 225mM NaCl, followed by 8 column volumes of 50mM BES pH 7.0, 500mM NaCl) was employed for specific elution of the CD4-gamma2 chimeric heavy chain homodimer. The CD4-gamma2 chimeric heavy chain homodimer was eluted
20   from the column in 50mM BES pH 7.0, 500mM NaCl. The peak fractions were then pooled and concentrated to yield a final protein concentration of at least 1 mg/ml. The pooled and concentrated fractions were then applied to a 120 ml column of Sephacryl S-300HR previously equilibrated with PBS, at a
25   flow rate of 8ml/hr. The CD4-gamma2 chimeric heavy chain homodimer fraction was specifically eluted in PBS, and concentrated to at least 1mg/ml.

Co-expression of CD4-IgG2HC-pRcCMV and CD4-kLC-pRcCMV in
30   mammalian cells to produce CD4-IgG2 chimeric heterotetramer

Stable expression
Dhfr- Chinese hamster ovary cells (CHO) are transfected with 20 micrograms of CsCl-purified DNA in a ratio of 1000:1000:1
35   CD4-IgG2HC-pRcCMV:CD4-kLC-pRcCMV:p410 (p410 is an expression plasmid containing the dhfr gene), although other ratios may

also be used. At approximately 3-5 days post-transfection, cells are placed in selective medium (nucleoside-free alpha MEM containing 5% dialyzed fetal calf serum). At approximately 10-15 days post-selection, individual cell

5 clones are picked. The clones are then analyzed for stable expression of CD4-IgG2 chimeric heterotetramers by several screening techniques, such as ELISA and precipitation with Protein A-sepharose beads followed by SDS-PAGE under reducing or non-reducing conditions. Clones expressing the

10 highest levels are subjected to successive rounds of amplification of the newly introduced DNA sequences in increasing concentrations of methotrexate. Stable CHO cell lines are thus generated which secrete high levels of CD4-IgG2 chimeric heterotetramer.

15

Purification of CD4-IgG2 chimeric heterotetramers from CHO conditioned media

CD4-IgG2 chimeric heterotetramers are purified using Protein A-Sepharose column chromatography. CHO cells secreting CD4-

20 IgG2 chimeric heterotetramers are grown to high density in roller bottles in medium containing alpha MEM with 5% IgG-free fetal calf serum. Conditioned media is collected, clarified by centrifugation, and diluted 1:1 with PBS either with or without detergent (i.e. Tween) in this and

25 subsequent buffers. The diluted media is then applied to a 5ml column of Protein A-Sepharose fast flow previously equilibrated with PBS, at a flow rate of 60ml/hour. After extensive washing, the bound material is eluted with 100mM glycine/HCl, pH 3.5, directly into an aliquot of 1M Tris.HCl

30 pH 8.0 to immediately neutralize the eluted fractions. Fractions are then analyzed by SDS-PAGE under reducing and non-reducing conditions followed by silver staining and pooled.

35 e)   Production of monoclonal anti-gp120 and anti-gp41 antibodies

The anti-gp120 and anti-gp41 monoclonal antibodies used in
the subject invention are commercially available. It is
also possible for one skilled in the art to make human,
murine, or humanized murine anti-gp120 or anti-gp41
5 antibodies by a variety of techniques.

For example it is possible to make human monoclonal anti-
gp41 antibodies as described infra. Briefly, peripheral
blood mononuclear cells (PBMCs) are isolated from the blood
10 of HIV-1-infected individuals who exhibit anti-gp41
antibodies in their serum. Epstein-Barr Virus (EBV,
obtained, for example, from B95-8 cell supernatants) is
added to the PBMC preparation which is then plated out in
96-well tissue culture plates at limiting dilution.
15 Colonies of EBV-immortalized B lymphocytes grow out and
those colonies producing anti-gp41 antibodies are identified
by methods well known to those skilled in the art. For
example, the media from these cells is used to
immunoprecipitate gp41 from metabolically radiolabelled
20 cells expressing gp120/gp41. Also, colonies producing anti-
gp41 antibodies may be identified by western blotting.
Colonies producing monoclonal antibodies specific for the
gp41 sequence ELDKWA may be identified by an assay such as
the enzyme-linked immunosorbent assay. Briefly, the ELDKWA
25 peptide is synthesized by methods well known to those
skilled in the art, or obtained commercially. The ELDKWA
peptide is used to coat the wells of a plastic 96 well
microtiter plate, and the wells are incubated with dilutions
of culture media from individual B lymphocyte colonies.
30 Antibodies which bind to the peptide are identified using,
for example, horseradish peroxidase-linked rabbit anti-human
immunoglobulin antibodies, followed by peroxidase substrate.

Colonies making the antibodies of interest are expanded and
35 fused with a suitable partner cell line, for example, a
mouse/human heteromyeloma. Hybrids are selected by culture

in selective medium in the presence of feeder cells, and stable antibody-secreting hybrids are cloned and expanded.

ii)   <u>Testing for synergistic blocking of HIV-1 envelope-</u>
5   <u>induced cell fusion by compositions of CD4-based</u>
        <u>proteins and antibodies to HIV-1 gp120 and gp41</u>

To test the compositions of molecules, a reproducible assay of HIV-1 envelope-mediated membrane fusion was used. Cells
10 expressing the HIV-1 envelope fuse with human cells expressing CD4 to make multinucleated syncytia. The fusion process is initiated by the attachment of HIV-1 gp120 to CD4, followed by HIV-1 envelope-mediated membrane fusion (22). These processes of attachment and fusion are also the
15 initial steps of HIV-1 infection of cells. Syncytium formation is a good model for studying HIV-1 attachment and fusion. Furthermore, anti-viral molecules which block these events also block syncytium formation. HIV-1 envelope-mediated cell fusion is also important, in its own right, as
20 a probable cause of cell death <u>in vivo</u> and as a mechanism for the transmission of HIV-1 from infected to uninfected cells.

In this assay, Chinese Hamster Ovary cells which stably
25 express HIV-1$_{HTLVIIIB}$ gp120 (160G7 cells) are plated out in 96-well tissue culture plates, at a concentration of 2×10^4 cells per well. In this assay, other cells expressing an HIV-1 envelope glycoprotein may be used instead of 160G7 cells. Such cells expressing an HIV-1 envelope glycoprotein
30 are widely available to those skilled in the art (e.g., NIH AIDS Research and Reference Reagent Program, Catalog No. 1247). Serial dilutions of the CD4-based proteins, antibodies, or a composition of the two are prepared in medium and added to the cells. 5-8 replicate wells are done
35 for each dilution. Two hours later, 2×10^4 human CD4+ T cells (C8166) are added to each well containing treated

160G7 cells. In this assay, other human CD4+ T cells may be
used instead of C8166 cells. Human CD4+ T cells are widely
available to those skilled in the art (e.g., NIH AIDS
Research and Reference Reagent Program, Catalog No. 404).
5 The plate is returned to 37°C for 48 hours before counting
the syncytia.

Syncytia between the 160G7 cells and C8166 appear as large
spherical structures which are easily distinguished from
10 unfused cells using light microscopy at 200x. Two fields of
syncytia are counted per well. For a given treatment, the
mean number of syncytia per field is calculated and
converted into the number of syncytia per well. The degree
of inhibition (fraction affected) is calculated in the
15 following manner: the mean number of syncytia per well for
a given treatment is subtracted from the control (mean
number of syncytia per well in the wells treated with medium
alone) and this figure is divided by the control.

20 To determine the relationship between the two drugs, the
Median Effect method of Chou and Talalay is employed as
described in section (iii) below.

iii)   Calculation of the relationship between agents:
25   synergy, additivity or antagonism

The Combination Index method of Chou and Talalay (23) was
used to calculate the degree of synergy, additivity or
antagonism between the various agents. The data obtained
30 using the assays above permits calculation of the inhibitory
ability of CD4-based molecules and antibodies to gp120 and
gp41 both alone and in combination. The dose of CD4-based
molecule or antibody is plotted against fractional
inhibition as shown in Figure 1.   These data are then
35 transformed using a multiple drug effect analysis based on
the median effect principle described by Chou and Talalay

(23). This involves a log-log dose response plot (the median effect plot), as shown in Figure 2, from which the slopes and intercepts are used for computer-assisted calculation of combination indices (CI) at different degrees

5 of inhibition (Figure 3).

For each molecule, D_1, D_2, or the combination $D_{1,2}$, the slope (m), median effect dose (D_m) and linear correlation coefficient (r) are determined from the median effect plot

10 (23). Next, the dose of each molecule or the combination required to give x fractional inhibition, $(D_x)_1$, $(D_x)_2$, and $(D_x)_{1,2}$, is calculated using the equation:

$$D_x = D_m[x/(1-x)]^{1/m}$$

15

Next, the contribution of D_1 and D_2 in the composition $(D_x)_{1,2}$ is calculated from the known dose ratio of the molecules. Finally, the combination index (CI) values are calculated using the equation:

20

$$CI = \frac{(D)_1}{(D_x)_1} + \frac{(D)_2}{(D_x)_2} + \frac{(D)_1(D)_2}{(D_x)_1(D_x)_2}$$

25

In these analyses, the mutually non-exclusive calculation method was used (23). This method is most appropriate if the molecules have different target sites, which is probably

30 correct in the case of CD4-based molecules and antibodies to the V3 loop of gp120 or to gp41. Mutually non-exclusive calculations are more conservative and give lower estimates of synergy than mutually exclusive calculations. A CI value of greater than 1 indicates antagonism. A CI value of 1

35 indicates an additive effect, and a CI value of less than 1 indicates synergy. In general, CI values are most important at the higher levels of inhibition since these correspond to the concentrations of drugs which would be significant in

<u>vivo</u>. In the case of the syncytium inhibition assay, 2 or 3 replicates of each experiment were done. These replicates were combined for purposes of analysis.

36

B. **Results and Discussion**

Several CD4-based molecules were tested including sCD4, CD4-
gamma1 chimeric heavy chain homodimers, CD4-gamma2 chimeric
5   heavy chain homodimers and CD4-IgG2 chimeric hetero-
tetramers. They were tested alone or in combination with
antibodies to gp120 or gp41. The antibodies included a
mouse antibody [9205] to the V3 loop of gp120 from the HIV-
1$_{HTLVIIIB}$ isolate, and a human antibody [2F5] to a conserved
10 epitope of HIV-1 gp41. Table 1 shows the amino-acid
sequence specificity of these antibodies.

Table 1: Target epitopes of antibodies to gp120 and gp41

15 Antibody	Species and Ig subclass	Target Domain on HIV-1
9205	Mouse IgG1	gp120 (V3 loop)
20 2F5	Human IgG3	gp41

25 Antibody	Target Epitope	
	residue number	amino acid sequence
30 9205	308-322	RIQRGPGRAFVTIGK
2F5	662-667	ELDKWA

35 Examples of the analyses are illustrated in Figures 1-3.
Figure 1 shows the inhibition of HIV-1 envelope-induced cell
fusion by different concentrations of sCD4, anti-V3 loop
antibody 9205 and a 1:1 composition thereof (based on mass,
equivalent to a 1:3 molar ratio of 9205:sCD4). It is clear
40 that the composition is more effective in blocking than
either agent alone. In Figure 2, this data is transformed
to a plot of Log Fa/Fu versus Log dose, where Fa is the
fraction affected (fractional inhibition) and Fu is the

37

fraction unaffected (1 - fraction affected). The curve for
the composition is not parallel with the curves for the
individual molecules, supporting the idea that molecules
are mutually non-exclusive in their effects (23). Figure 3

5 shows CI plotted against fractional inhibition, and
demonstrates synergy (CI less than 1) at the higher levels
of inhibition.

The same method was used to analyze inhibition of HIV-1
envelope-mediated cell fusion by a number of compositions of

10 CD4-based molecules and antibodies to gp120 and gp41. The
results are shown in Table 2.

Table 2:   <u>Inhibition of HIV-1 envelope-mediated cell fusion by compositions of CD4-based molecules and antibodies to gp41 or the V3 loop of gp120</u>

	Antibody	IC50 ug/ml	CD4-based molecule	IC50 ug/ml	Molar ratio (Ab/CD4)
Anti-V3 loop antibody:					
1.	9205	4.5	sCD4	5.4	1:3
2.	9205	6.6	gamma1	2.8	1:1.5
3.	9205	3.2	gamma2	3.0	1:1.5
4.	9205	3.3	gamma2	2.0	1:6
Anti-gp41 antibody:					
5.	2F5	85.9	sCD4	5.7	1:3
6.	2F5	27.3	gamma2	1.6	1:1.5

	Number of Replicates	CI at 75% inhibition	CI at 90% inhibition	CI at 95% inhibition
1.	3	0.52	0.30	0.21
2.	2	0.86	0.69	0.59
3.	2	0.71	0.70	0.71
4.	2	0.74	0.59	0.52
5.	3	0.66	0.65	0.65
6.	3	0.70	0.41	0.29

Key: gamma1 = CD4-gamma1 chimeric heavy chain homodimer
gamma2 = CD4-gamma2 chimeric heavy chain homodimer

39

In all cases, an r value greater than 0.9 was obtained for
the log/log plots, indicating a good fit between log dose
and log Fa/Fu (23). The molar ratio of the molecules in each
composition is indicated.   In all cases the more
5   conservative mutually non-exclusive calculation method was
used.   It can be seen from Table 2 that all compositions of
molecules tested have combination indices below 1, and
therefore are synergistic at higher levels of inhibition
(75% inhibition or above), which are most relevant as
10   described supra. For example, the composition of CD4-gamma2
chimeric heavy chain homodimer and monoclonal anti-gp41
antibody is synergistic, with CI values as low as 0.29.
This indicates that the amount of the composition required
to block HIV-1 envelope-mediated cell fusion is smaller than
15   would be expected based on the blocking abilities of either
molecule used alone.

The most useful compositions comprise molecules which can
neutralize a wide variety of HIV-1 isolates. The CD4-based
20   molecules fulfil this criterion.   Neutralization by
antibodies to the V3 loop of gp120 is often limited to a
number of closely related isolates, and where this is the
case, these antibodies alone would be less useful for
blocking HIV-1 infection.   In contrast, the anti-gp41
25   antibody (e.g., 2F5) neutralizes a wider range of isolates
(18).   Therefore, compositions of CD4-based proteins and
antibodies to gp41 may be the most advantageous for clinical
use in connection with the prophylaxis and treatment of HIV-
1 infection.
30
When using compositions of molecules in vivo, such as in the
case of post-exposure prophylaxis, it is advantageous to use
CD4-based molecules with half-lives of one day or more, such
as the CD4-gamma2 chimeric heavy chain homodimer or the CD4-
35   IgG2 chimeric heterotetramer.   Th se molecules have
advantages over their IgG1 counterparts, particularly in

their lack of Fc-mediated function as described _supra_. In clinical situations, therefore, compositions of the CD4-gamma2 chimeric heavy chain homodimer or CD4-IgG2 chimeric heterotetramer, and broadly neutralizing antibodies such as

5 anti-gp41 antibodies, are particularly advantageous.

C. **Examples of clinical us s of the c mpositions of the subject invention**

5 Example 1 - <u>Occupational Exposure to HIV-1</u>

Health care workers exposed to HIV-1-contaminated blood or other bodily fluids can become infected with the virus. Common routes of exposure include, but are in no way limited
10 to, the following: penetration of the skin by an uncapped syringe needle coated with HIV-1-containing bodily fluids ("needle-stick-injury"); cuts caused by scalpels or other instruments during surgery on HIV-1-infected individuals; and splashes of blood or other bodily fluids in the eyes or
15 on cracked skin.

To reduce the risk of HIV-1 transmission in the health care setting, the composition of the subject invention would be administered to a health care worker who was exposed to HIV-
20 1-contaminated fluids, by routes such as those listed above. The composition may be administered by, <u>inter alia</u>, intravenous bolus, continual IV infusion, intramuscular injection, subcutaneous injection or directly to the wound or exposed skin. A combination of these routes may be used.
25 Depending on the route of administration and the nature of the treatment, the composition of the subject invention might be given continuously or intermittently. The treatment may be most effective if the composition were administered as soon after the exposure as possible, for
30 example within one or two hours after exposure.

Example 2 - <u>Mother To Infant Transmission Of HIV-1</u>

Newborns of HIV-1-infected mothers often become infected
35 with HIV-1. In many cases, infection occurs around the time of birth, due to the exposure of the baby to HIV-1-

42

contaminated blood and other bodily fluids from the mother.

To reduce the risk of HIV-1 transmission in this setting, the composition of the subject invention would be
5   administered to the mother prior to delivery, or to the baby after delivery, or to both. The possible routes of administration include those listed in Example 1, <u>supra</u>. The purpose of treating the mother would be to reduce the infectivity of the maternal blood or other bodily fluids
10   prior to delivery. As an example, the treatment may comprise delivering to the mother a series of intravenous bolus injections of the composition starting several hours or more before birth. Subsequently, the newborn would be treated with the composition in order to reduce the
15   infectivity of any virus which had entered its body around the time of birth. For example, within one or two hours after birth, the newborn may be treated with a continuous IV infusion of the composition for several days.

20

43

Referenc s

1.   Macatonia, R.L. et al. (1990) Immunology 71, 38-
        45.

2.   Langhoff, E. et al. (1991) Proc. Natl. Acad. Sci.
        USA 88, 7998-8002.

3.   Lasky, L.A. et al. (1987) Cell 50, 975-985.

4.   Sattentau, Q.J., and Moore, J.P. (1991) J.Exp.Med.
        174, 407-415.

5.   Maddon, P.J. et. al. (1988) Cell 54, 865-874.

6.   Maddon, P.J. et al. (1988) PCT WO88/01304.

7.   Moore, J.P. et al. (1990) Science 250, 1139-1142.

8.   Schooley, R.T. et al. (1990) Ann. Internal Med.
        112, 247-253.

9.   Kahn, J.O. et al. (1990) Ann. Internal Med. 112,
        254-261.

10.   Daar, E.S. et al. (1990) Proc. Natl. Acad. U.S.A.
        87, 6574-6578.

11.   Capon, D.J. et al. (1989) Nature 337, 525-531.

12.   Byrn, R.A. et al. (1990) Nature 344, 667-670.

13.   Ward, R.H. et al. (1991) Nature 352, 376-377.

14.   Pound, J.D., and Walker, M.R. (1990) In: The Human

IgG Subclasses, Ed. F.Shakib. Pergamon Press, Oxford, UK. pp.111-133.

15.   Bolognesi, D.P. (1990) TIBTech 8, 40-45.

16.   Skinner, M.A. et al. (1988) J. Virol. 62, 4195-4200.

17.   Thall, M. et al. (1992) J. Virol. 66, 5635-5641.

18.   Muster, T. et al. (1992) In: Proceedings of the 7th Colloque Des Cent Gardes, Ed. O. Robert, L'Imprimerie Martineau, 69100 Villeurbanne, France.

19.   Tilley, S.A., et al. (1992) AIDS Res. Hum. Retrovir. 8, 461-467.

20.   Buchbinder et al. (1992) AIDS Res. Hum. Retrovir. 8, 425-427.

21.   Thali, M. et al. (1992) J. AIDS 5, 591-599.

22.   Dalgleish et al. (1984) Nature, 312, 763-767.

23.   Chou, T-C. (1991) In: Synergism and Antagonism in Chemotherapy, Eds. Chou, T-C and Rideout, D.C. Academic Press, Inc. San Diego. pp. 61-102.

24.   Durda P.J. et al. (1990) AIDS Res. Hum. Retrovir. 6, 1115-1123.

25.   Remington's Pharmaceutical Science, 16th Ed., Mack Ed. (1990).

What is claimed is:

1.   A composition comprising (a) a carrier, (b) a CD4-
based protein, and (c) an antibody which
specifically binds to an epitope present on an HIV-
1 envelope glycoprotein and required for the fusion
of a CD4-containing membrane with a membrane
containing the HIV-1 envelope glycoprotein, the
ratio of CD4-based proteins to antibodies in the
composition being such that the ratio of gp120-
binding sites on the CD4-based proteins to epitope-
binding sites on the antibodies is between about
0.01 and about 100.

2.   The composition of claim 1, wherein the ratio of
gp120-binding sites to epitope-binding sites is
between about 0.1 and about 10.

3.   The composition of claim 2, wherein the ratio of
gp120-binding sites to epitope-binding sites is
between about 1 and about 10.

4.   The composition of claim 3, wherein the ratio of
gp120-binding sites to epitope-binding sites is
between about 1.5 and about 6.

5.   The composition of claim 1, wherein the carrier is
a pharmaceutically acceptable carrier.

6.   The composition of claim 5, wherein the composition
is a liquid and the pharmaceutically acceptable
carrier is an aqueous buffer.

7.   The composition of claim 5, wherein the composition
is a solid and the pharmaceutically acceptable

46

carrier is an excipient.

8.   The composition of claim 1, wherein the CD4-based
        protein is sCD4.

9.   The composition of claim 1, wherein the CD4-based
        protein is a CD4-immunoconjugate.

10.   The composition of claim 9, wherein the CD4-
        immunoconjugate is a CD4-gamma1 chimeric heavy
        chain homodimer.

11.   The composition of claim 9, wherein the CD4-
        immunoconjugate is a heterotetramer comprising two
        heavy chains and two light chains, both heavy
        chains being either a) IgG1 heavy chains or b)
        chimeric CD4-IgG1 heavy chains, and both light
        chains being a) kappa light chains, b) lambda light
        chains c) chimeric CD4-kappa light chains, or d)
        chimeric CD4-lambda light chains, with the proviso
        that either both heavy chains or both light chains
        or all four chains are CD4 chimeras.

12.   The composition of claim 11, wherein the chimeric
        CD4-IgG1 heavy chains are encoded by the expression
        vector designated CD4-IgG1HC-pRcCMV (ATCC No.
        75192), and the chimeric CD4-kappa light chains are
        encoded by the expression vector designated CD4-
        kLC-pRcCMV (ATCC No. 75194).

13.   The composition of claim 9, wherein the CD4-
        immunoconjugate is a CD4-gamma2 chimeric heavy
        chain homodimer.

14.   The composition of claim 13, wherein the CD4-gamma2
        chimeric heavy chain homodimer is the CD4-gamma2

chimeric heavy chain homodimer whose chains are
encoded by the expression vector designated CD4IgG$_2$-
pcDNA1 (ATCC No. 40952).

5   15.   The composition of claim 9, wherein the CD4-
immunoconjugate is a heterotetramer comprising two
heavy chains and two light chains, both heavy
chains being either a) IgG2 heavy chains or b)
chimeric CD4-IgG2 heavy chains, and both light

10   chains being a) kappa light chains, b) lambda light
chains c) chimeric CD4-kappa light chains, or d)
chimeric CD4-lambda light chains, with the proviso
that either both heavy chains or both light chains
or all four chains are CD4 chimeras.

15

16.   The composition of claim 15, wherein the chimeric
CD4-IgG2 heavy chains are encoded by the expression
vector designated CD4-IgG2HC-pRcCMV (ATCC No.
75193), and the chimeric CD4-kappa light chains are

20   encoded by the expression vector designated CD4-
kLC-pRcCMV (ATCC No. 75194).

17.   The composition of claim 1, wherein the antibody is
capable of forming a complex with an epitope

25   present on HIV-1 gp120 envelope glycoprotein.

18.   The composition of claim 17, wherein the antibody
is capable of forming a complex with an epitope
present on the V3 loop of HIV-1 gp120 envelope

30   glycoprotein.

19.   The composition of claim 1, wherein the antibody is
capable of forming a complex with an epitope
present on HIV-1 gp41 envelope glycoprotein.

35

20.   The composition of claim 19, wherein the antibody

48

is capable of forming a complex with an epitope
present on HIV-1 gp41 envelope glycoprotein, said
epitope comprising the amino acid sequence ELDKWA.

5   21.   The composition of claim 20, wherein the antibody
            is the monoclonal antibody designated 2F5.

    22.   A method of treating a subject which comprises
            administering to the subject an amount of the
10   composition of claim 5 effective to reduce the
            likelihood of the subject's becoming infected with
            HIV-1.

    23.   The method of claim 22, wherein the subject is a
15   newborn infant.

    24.   The method of claim 22, wherein the subject is a
            medical practitioner.

20 25.   A pharmaceutical composition comprising an amount
            of the composition of claim 5 effective to reduce
            the likelihood of a subject's becoming infected
            with HIV-1.

25 26.   A method of treating an HIV-infected subject, which
            comprises administering to the subject an amount of
            the composition of claim 5 effective to reduce the
            rate of spread of HIV-1 infection in the subject.

30 27.   A pharmaceutical composition comprising an amount
            of the composition of claim 5 effective to reduce
            the rate of spread of HIV-1 infection in an HIV-1-
            infected subject.

35 28.   A method of decontaminating a fluid containing HIV-
            1, which comprises contacting the fluid with the

49

composition of claim 1, under conditions such that the composition of claim 1 forms a complex with the HIV-1 therein, thereby decontaminating the fluid.

5   29.   A method of decontaminating a fluid containing HIV-1, which further comprises contacting the fluid with the composition of claim 1, under conditions such that the composition of claim 1 forms a complex with the HIV-1 therein, and removing the

10   complex so formed from the fluid, thereby decontaminating the fluid.

Figure 1

Figure 2

Figure 3

Combination Index vs. Fraction of syncytia inhibited

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :A61K 39/42; C07K 15/00, 15/28;
US CL :424/86; 514/2, 8, 12; 530/388.35

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/85.8, 86, 89; 435/5,69.6, 70.21, 172.2, 172.3, 240.27, 252.3, 320.1; 514/2, 8, 12; 530/350, 380, 387.3,388.35

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO, 88/01304, (MADDON et al.) 25 FEBRUARY 1988, see entire document	1-29
Y	VII INTERNATIONAL CONFERNECE ON AIDS, issued 16-21 JUNE 1991, Tilley et al., "Human monoclonal antibodies against the putative CD4 binding site and the V3 loop of HIV gp120 act in concert to neutralize virus," Abstract No. M.A.70, see entire document.	1-29
Y	SIXIEME COLLOQUE DES CENT GARDES, issued 1991, Tilley et al., "Potent neutralization of HIV-1 by human and chimpanzee monoclonal antibodies directed against three distinct epitope clusters of gp120," pages 211-216, see paragraph bridging pages 211-213.	1-29

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be part of particular relevance		
"E"	earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed	"&"	document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
28 MAY 1994	JUN 06 1994

Name and mailing address of the ISA/US	Authorized officer
Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	ROBERT D. BUDENS
Facsimile No. (703) 305-3230	Telephone No. (703) 308-019f

Form PCT/ISA/210 (second sheet)(July 1992)★

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	AIDS RESEARCH AND HUMAN RETROVIRUSES, Vol. 7, No. 12, issued 1991, Kennedy et al., "Analysis of synergism/antagonism between HIV-1 antibody-positive human sera and soluble CD4 in blocking HIV-1 binding and infectivity," pages 975-981, see entire document.	1-29
Y	NATURE, Vol. 337, issued 09 FEBRUARY 1989, Capon et al., "Designing CD4 immunoadhesins for AIDS therapy," pages 525-531, see entire document.	1-29
Y	NATURE, Vol. 339, issued 04 MAY 1989, Traunecker et al., "Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules," pages 68-70, see entire document.	1-29
Y	NATURE, Vol. 344, issued 12 APRIL 1990, Byrn et al., "Biological properties of a CD4 immunoadhesin," pages 667-670, see entire document.	1-29
Y	NATURE, Vol. 352, issued 01 AUGUST 1991, Ward et al., "Prevention of HIV-1 IIIB infection in chimpanzees by CD4 immunoadhesin," pages 434-436, see entire document.	1-29
T	VIROLOGY, Vol. 197, issued 1993, Potts et al., "Synergistic Inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies," pages 415-419, see entire document.	1-29
T	AIDS RESEARCH AND HUMAN RETROVIRUSES, Vol. 9. No. 7, issued 1993, Allaway et al., "Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41," pages 581-587, see entire document.	1-29
A	CLINICAL AND EXPERIMENTAL IMMUNOLOGY, Vol. 88, issued 1992, Fahey et al., "Status of immune-bsed therapies in HIV infection and AIDS," pages 1-5, see entire document.	1-29
A	DRUGS, Vol. 34, issued 1987, Sandstrom et al., "Antiviral therapy in AIDS: Clinical pharmacological properties and therapeutic experience to date," pages 372-390, see entire document.	1-29

INTERNATIONAL SEARCH REPORT

Box I   Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
   because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
   because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II   Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Telephone Practice

   I.   Claims 1-27, drawn to compositions containing CD4 analogs, anti-HIV antibodies, and a first method of use, classified in Class 530, subclass 388.35, and Class 424, subclass 86.

   II.   Claims 28-29, a second method of use, drawn to methods of decontaminating a fluid, classified in Class 530, subclass 413.

Inventions I and II are related as product and processes of use and are not so linked by a special technical feature within the meaning of PCT Article 13.2 as to form a single general inventive concept.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest   ☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1))(July 1992)